Regeneron Pharmaceuticals, Pfizer, AbbVie, AstraZeneca, Biogen and Alnylam Pharmaceuticals will invest $10 million each to sequence the exomes of 500,000 people whose health data are stored in the UK Biobank by the end of 2019, and the resulting data will be available to researchers worldwide after a six- to 12-month exclusivity period for consortium members, according to Regeneron. "This is a great example of the life sciences industry stepping up and giving back something that is going to help society while also accelerating our own efforts to come up with new drug targets and new medicines," said Regeneron President and Chief Scientific Officer George Yancopoulos.
Drugmakers collaborate on exome sequencing initiative
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.